Key result
ACE/Ang II/AT1R signaling and estrogen deficiency drive bone loss in type 2 diabetes.
Why the study?
While substantial literature exists on the effects of RAAS and osteoporosis in T2D, the evidence had not yet been consolidated.
This narrative review consolidates mechanistic evidence linking local and systemic RAAS upregulation with estrogen deficiency and osteoporosis in type 2 diabetes, suggesting potential osteoprotective benefits of RAAS blockade.
Answers are grounded in this paper and cite their sources.
May suggest osteoprotective effects of RAAS blockade in T2D osteoporosis; hypothesis-generating and requires prospective trials.
Type 2 diabetes (T2D) is associated with a plethora of comorbidities, including osteoporosis, which occurs due to an imbalance between bone resorption and formation. Numerous mechanisms have been explored to understand this association, including the renin-angiotensin-aldosterone system (RAAS). An upregulated RAAS has been positively correlated with T2D and estrogen deficiency in comorbidities such as osteoporosis in humans and experimental studies. Therefore, research has focused on these associations in order to find ways to improve glucose handling, osteoporosis and the downstream effects of estrogen deficiency. Upregulation of RAAS may alter the bone microenvironment by altering the bone marrow inflammatory status by shifting the osteoprotegerin (OPG)/nuclear factor kappa-Β ligand (RANKL) ratio. The angiotensin-converting-enzyme/angiotensin II/Angiotensin II type 1 receptor (ACE/Ang II/AT1R) has been evidenced to promote osteoclastogenesis and decrease osteoblast formation and differentiation. ACE/Ang II/AT1R inhibits the wingless-related integration site (Wnt)/β-catenin pathway, which is integral in bone formation. While a lot of literature exists on the effects of RAAS and osteoporosis on T2D, the work is yet to be consolidated. Therefore, this review looks at RAAS activity in relation to osteoporosis and T2D. This review also highlights the relationship between RAAS activity, osteoporosis and estrogen deficiency in T2D.
No takes yet. Share an insight, caveat, or question.
Mkhize et al. (2023) conducted a review in Type 2 diabetes, osteoporosis, and estrogen deficiency. Renin-angiotensin-aldosterone system (RAAS) activity was evaluated. Upregulated ACE/Ang II/AT1R signaling and estrogen deficiency in type 2 diabetes promote osteoclastogenesis and inhibit osteoblast formation, contributing to osteoporosis.
Synapse has enriched 10 related papers. Consider them for comparative context: